Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kala BioFRA:27F 18 PEG Ratio is 0.00 as of Jul. 18, 2026. GuruFocus rates FRA:27F with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 93 Biotechnology companies, Kala Bio ranks worse than 1075267.74% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Kala Bio's PE Ratio without NRI is 0.00. Kala Bio's 5-Year EBITDA growth rate is 51.40%. Therefore, Kala Bio's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Kala Bio's PEG Ratio or its related term are showing as below:
FRA:27F's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.99 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Kala Bio (FRA:27F) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Kala Bio PEG Ratio Related Terms
Kala Bio PEG Ratio Historical Data
* Premium members only.
The historical data trend for Kala Bio's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kala Bio's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Kala Bio's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Kala Bio (FRA:27F) has a PEG Ratio of 0.00 as of Jul. 18, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Kala Bio and its competitors. According to the industry distribution chart, Kala Bio ranks #999999 out of 93 companies in the Biotechnology industry.
Is Kala Bio's PEG Ratio too high?
Kala Bio's current PEG Ratio is 0.00. Based on the distribution chart, Kala Bio ranks #999999 out of 93 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kala Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's PEG Ratio compare to MGX and HYPD?
According to the Biotechnology industry distribution chart, Kala Bio ranks #999999 out of 93 companies for PEG Ratio. This places Kala Bio in the lower half of its industry. The industry median PEG Ratio is 1.99. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.99, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Kala Bio and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (FRA:27F) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Kala Bio's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Kala Bio (FRA:27F), the current PEG Ratio is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
18GF Score
Get the complete analysis for FRA:27F
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:27F has been successfully added to your 
